United States: CDRH Issues Final Rule On Appeals, Excluding De Novos From 517A

On 2 July 2019 the U.S. Food and Drug Administration (FDA or the agency) issued a final rule1 updating the processes for appeal of certain FDA decisions related to medical devices regulated by the Center for Devices and Radiological Health (CDRH). The final rule, which takes effect on 1 August 2019, represents the culmination of the rule-making proposed in January 2018 (the proposed rule, discussed here),2 finalizing the category of "517A decisions," previously termed "significant decisions," which are specified by section 517A of the Food, Drug, and Cosmetic Act (FDCA). The final rule also confirms the timeframes for requesting supervisory review and for FDA's responses to such requests as outlined in the proposed rule.

In conjunction with the 2 July final rule, FDA issued two final guidance documents that revise, update, and replace several preexisting guidances.3 The first guidance, entitled "Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers about 517A" (Q&A guidance), finalizes a draft of the guidance released on 29 September 2017 and replaces a 2014 guidance explaining FDA's approach to implementing FDCA Section 517A.4 The second guidance, entitled "Center for Devices and Radiological Health (CDRH) Appeals Processes" (appeals guidance), finalizes a draft guidance issued on 28 December 2011 and supersedes three prior final guidances.5

Of note, this final rule and associated guidance documents relate to formal appeals of FDA decisions, which should generally come after an "informal" interaction with the agency to resolve issues. The appeal process is distinct from interactive review communications (e.g., 10-day clarification calls and submission issue meeting requests), and those invoking FDA's new least burdensome flag provisions for 510(k) notices, which can be used to request supervisory review of discrete issues raised in FDA requests for additional information.

Final rule closely tracks proposed rule, excluding De Novos from 517A decisions

The final rule takes effect on 1 August 2019 and proposes almost the exact regulatory language as the 2018 proposed rule. Notably, while acknowledging the importance of De Novo decisions, FDA declined to expand the definition of "517A decisions" to include the grant or decline of a De Novo request, despite comments to the proposed rule that requested such an expansion. FDA's decision rests on the fact that Section 517A of the FDCA does not identify decisions on requests under Section 513 as one of the types of significant decisions subject to that section.

FDA also explained that, as in the proposed rule, it decided not to call decisions subject to Section 517A of the FDCA "significant decisions" but rather "517A decisions" because the agency did not want to imply that other CDRH decisions were "non-significant" in terms of importance. Decisions not subject to this section are termed "non-517A decisions." The final rule also retains the proposed timelines for requesting appeals of 517A and non-517A decisions outlined in the proposed rule, as well as FDA's timelines for responding.

Notable changes to the final guidances

The Q&A guidance, which takes effect on 1 August 2019 and which had not been updated since the draft released in 2017, has now been updated to reflect the changes in both the proposed and final rules, described in our prior alert and above.

The final appeals guidance differs from its prior version in several notable ways:

  • The section on supervisory review has been updated to reflect the proposed and final rules regarding 517A decisions.
  • The supervisory review section has been updated to reflect the reorganization of CDRH, specifying that the general order of appeal is Division of Health Technology → Office of Health Technology → Office of Product Evaluation and Quality → Center → Commissioner.
  • A new section regarding bias and retaliation has been added, which recommends referral of allegations of bias or retaliation after challenging an agency decision to the Ombudsman in most cases. This section also describes the possibility of bringing such claims to the FDA Office of Internal Affairs or the Department of Health and Human Services Office of the Inspector General.
  • Interestingly, the appeal guidance also discusses referral of a matter in dispute to external experts, often referred to as a "Panel Homework Assignment," and notes that the agency will draft a document stating the issues in dispute and attach relevant documents for review. It states that the review authority "may provide to the submitter a copy of the document for comment and may also allow the submitter to suggest areas of expertise relevant to the issues in dispute, although the final version of the document and the specific individuals selected as SMEs are determined by the review authority." This is in contrast to our recent experience, where the agency has generally kept such homework assignments confidential.
  • The guidance also states that FDA intends to follow the 517A-decision response time frame even for non-517A-decision responses, with the significant caveats that it is not required to do so and this will only be done if resources permit. This could be helpful for appeals of De Novo decisions, which are non-517A decisions, though it is clearly not binding on the agency.
  • The appeals guidance provides a bit more leeway for including new information in appeals, stating that, while the inclusion of new information may cause the appeal to be referred back down for reconsideration, as is typically done, the review authority may also allow the inclusion of new information in order to expedite a decision.

Key takeaways

  • The final rule regarding 517A decisions is largely consistent with the proposed rule providing updates and clarifications on use of FDA's appeals process, including considerations of when an appeal is appropriate and procedural requirements for filing an appeal.
  • The agency's decision to exclude De Novo decisions from 517A decisions is significant, given that decisions on De Novo requests have similar regulatory consequences as decisions on 510(k)s and premarket approval applications – not to mention the significant user fee associated with these requests. In the past, our clients have requested and obtained from FDA substantive summaries of De Novo decisions consistent with the requirements of 517A(a) of the FDCA, which requires that this information be available detailing the scientific and regulatory rationale for any significant decision, suggesting some inconsistency within agency practice regarding the status of such decisions. FDA's hesitancy to include decisions on De Novo requests within the scope of 517A, which is grounded in their absence in the underlying statutory text, implies that a legislative amendment might be necessary to reverse course. The narrow construction and interpretation of the applicability of what is considered a 517A decision ripe for appeal and therefore subject to strict timelines for review underscores the importance of detailed interaction with FDA during the regulatory strategy development phase and prior to the issuance of final decisions.
  • The Q&A guidance and appeals guidance were updated to reflect the final rule, and the appeals guidance includes additional changes, such as inclusion of a section indicating that the process should not be used to raise allegations of bias or retaliation. The appeals guidance further notes that the agency intends to follow 517A time frames for non-517A appeals as well; however, this is a nonbinding commitment and it remains to be seen how CDRH will handle the timing of non-517A appeals, particularly those related to De Novo decisions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions